Leading pharmaceutical organizations select NavaX AI to transform global pharmacovigilance operations with enterprise AI
Boston, Massachusetts, USA — June 30, 2026 — ArisGlobal, an AI-first technology company at the forefront of life sciences and creator of LifeSphere®, today announced that two additional global pharmaceutical organizations have selected NavaX AI to streamline global PV operations leveraging the most advanced AI capabilities.
The two organizations—one a leading European pharmaceutical company, and the other a leading Japan-based pharmaceutical company —will leverage NavaX AI to intelligently harness structured and unstructured safety & clinical data from source documents, transitioning towards AI-driven pharmacovigilance operations, accelerating pharmacovigilance workflows while improving consistency, quality, and compliance.
The latest customer wins reinforce growing industry momentum as life sciences organizations move beyond evaluating artificial intelligence and begin deploying production-scale AI to address increasing case volumes, resource constraints, and evolving regulatory expectations.
“Today’s announcement demonstrates that customers are increasingly embracing production AI to transform critical global pharmacovigilance operations—not years from now, but today. As adoption continues to accelerate, we’re seeing organizations move from isolated use cases to enterprise-wide AI strategies,” said Aman Wasan, Chief Executive Officer, ArisGlobal. “NavaX AI was never designed as another AI pilot or point solution. We have built an enterprise AI platform that enables life sciences organizations to operationalize AI safely, compliantly, and at scale, and we’re pleased two more organizations are leveraging NavaX AI.”
These latest implementations continue ArisGlobal’s rapid NavaX AI momentum as pharmaceutical organizations increasingly deploy AI across real-world safety operations. Customers are adopting NavaX AI not simply to automate individual tasks, but to establish a scalable AI foundation capable of supporting future use cases across pharmacovigilance, regulatory affairs, quality, and medical affairs.
With every new production deployment, ArisGlobal continues to demonstrate that enterprise AI in life sciences has moved beyond proof-of-concept and into measurable operational value, delivering true and positive return on investment (ROI) to the global pharmaceutical companies.
